Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the Week of 21st September 2026 - 28th September 2026 ( FDA, Approval ) Mirum obtains FDA approval for ATEBRIOZ tablets to reduce the volume of HO in those aged 12 years and older with FOP ( FDA, Approval ) Lantheus gets final approval from FDA for BRAVNETSA to treat adults with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors ( FDA, Approval ) Eli Lilly gains FDA approval for ONSWIK, indicated along with diet and exercise, to control high blood sugar in adults with type 2 diabetes ( FDA, Approval ) FDA grants approval to Elevar Therapeutics' LYRFIGTU as a treatment option for CCA with FGFR2 fusion or other rearrangement Pg 1/5 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 21st Sep – 28th Sep in the world of pharma and healthcare!

September 28, 2026

Highlights from the week of 14th Sep - 21st Sep Alfasigma ( CHMP, Positive Opinion ) CHMP issues positive opinion for Alfasigma's filgotinib to treat axSpA in patients with an inadequate response to conventional therapy Novo Nordisk ( CHMP, Positive Opinion ) Novo Nordisk gets positive CHMP opinion for SOGROYA, administered once weekly, for children with ISS and persistent growth disturbances AstraZeneca ( CHMP, Positive Opinion ) CHMP recommends positive opinion to AstraZeneca's ENHERTU as a monotherapy for the adjuvant treatment of adults with resected HER2-positive breast cancer Roche ( CHMP, Positive Opinion ) Roche gains a positive CHMP opinion for its OCREVUS IV infusion to treat patients aged 10 years and older with RMS All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 14th Sep – 21st Sep in the world of pharma and healthcare!

September 21, 2026

Highlights from the Week of 07th September 2026 - 14th September 2026 ( FDA, Accelerated Approval ) FDA provides accelerated approval to Bayer's sevabertinib to treat locally advanced or metastatic NSCLC with HER2/ERBB2 tumors ( FDA, Priority Review ) FDA accepts Takeda's TAK-279 under Priority Review to treat adults with moderate-to-severe plaque psoriasis ( FDA, Priority Review ) Genentech receives Priority Review from FDA for its sBLA, ENSPRYNG to treat MOGAD ( FDA, Fast Track ) Sobi obtains Fast Track designation from FDA for pacritinib to treat VEXAS syndrome Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare!

September 14, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

2026 RBC Capital Markets Global Healthcare Conference 2026 RBC Capital Markets Global Healthcare Conference May 19,2026 To May 20,2026 May 20 May 19 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 19,2026 To May 20,2026

May 18, 2026

Bank of America Securities Healthcare Conference May 12,2026 To May 14,2026 May 12 May 13 May 14 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 12,2026 To May 14,2026

May 11, 2026

Q1 2026 Earning Conference Call May 04,2026 To May 07,2026 May 04 May 05 May 07 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 04,2026 To May 07,2026

May 5, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

WORLD Schizophrenia Day 2026 Definition Schizophrenia is a serious mental illness that affects how a person thinks, feels, and behaves Global Prevalence US Prevalence 1.22 M 23.6 M People live with Schizophrenia worldwide New cases are diagnosed globally each year Prevalence of schizophrenia & related psychotic disorders 0.25% & 0.64% Late adolescence and the twenties, Earlier among men than among women 0% 0.1% 0.2% 0.3% 0.4% 0.5% Types of Schizophrenia Paranoid delusions focusing on the self Belief in being targeted by people, objects 'others'. Excitement & stupor phases Reluctance to move limbs/body Symptoms that don't clearly fit one of the other types Bizarre behavior, delusions & hallucinations Often occurs in adolescence Paranoid Catatonic Disorganized Undifferentiated Symptoms Positive Symptoms : any change in behaviour or thoughts Negative symptoms : often appear months or years before a person experiences delusions or hallucinations Positive Symptoms Delusions Confused thinking and speech Hallucinations Negative Symptoms Lack of Motivation Social Withdrawal Emotional Flatness Cognitive Symptoms Attention issues Problem-solving Impaired verbal ability Diagnosis > 2 of the specified symptoms according to DSM-5 classification for a duration of 1 month Recent update Clinical Interview for DSM-5 (SCID) How long symptoms have been appearing Rule out other possible illnesses Rule out substance use SNPs may now serve as biomarkers Treatment 1st Generation 2nd Generation New MOA MOA Typical mGPCR antagonists Atypical mGPCR antagonists M1/M4 agonist Drug Name Company Name Drug Name Company Name Drug Name Company Name Drugs Haloperidol Clozapine COBENFY Chlorpromazine Olanzapine Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

Today, we recognize Bipolar Disorder and Schizophrenia Awareness and stand in support of individuals, families, and communities affected by these conditions. By encouraging understanding, empathy, and open conversations, we can help reduce stigma and promote mental well-being for all.

May 24, 2026

INFLAMMATORY BOWEL DISE SE IBD is an umbrella term for a group of conditions that cause swelling and inflammation of the tissues in the digestive tract Global Prevalence and Incidence Country-wise affected population Prevalence 2.4-3.1M 229.7 per 100,000 2.5-3 M Incidence Low Low with increase 0.18 M High TYPES OF IBD Crohn's disease Ulcerative colitis Crohn's disease (CD): It can affect any part of the digestive tract from mouth to anus and causes deep, tissue-layer inflammation Ulcerative colitis (UC): It affects only the colon and rectum's inner lining, causing inflammation and ulcers DIAGNOSIS Blood Test Stool Test Upper Endoscopy Colonoscopy Tissue Biopsy Imaging Studies Risk factors Causes of inflammatory Bowel Disease Medium Women face a higher risk of CD; men face a higher risk of UC Smoking affects development and severity of Crohn's Commonly diagnosed between ages 15-35 Luminal Factors Microbiome Intestinal Immune System Alterations Environmental Factor Genetic Predisposition SYMPTOMS Loss of appetite Fatigue Stomach aches and cramps Weight loss Diarrhea Blood in your stool TREATMENT Surgery Bowel resection Top-down approach Nutritional support Probiotics Biologic therapy Adalimumab & Infliximab Immunosuppressants Methotrexate, Azathioprine & Mercaptopurine Corticosteroids Budesonide, Methylprednisolone & Prednisolone 5-ASA | Antibiotics 5 ASA- Mesalamine & Sulfasalazine | Antibiotics- Ciprofloxacin & Metronidazole Step-up approach Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜

May 19, 2026

High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️

May 17, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of Use

Privacy Policy

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message